<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021757</url>
  </required_header>
  <id_info>
    <org_study_id>CP 64647</org_study_id>
    <nct_id>NCT05021757</nct_id>
  </id_info>
  <brief_title>Disrupt CAD III Post-Approval Study (PAS)</brief_title>
  <official_title>New Enrollment Post Approval Registry for the Shockwave Intravascular Lithotripsy (IVL) System With Shockwave C2 Coronary Intravascular Lithotripsy (IVL) Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shockwave Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shockwave Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study design is a prospective, multicenter, observational, single-arm post-approval study&#xD;
      using data collected in the National Cardiovascular Data Registry (NCDR®) CathPCI Registry®.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subject Population: Patients ≥18 years of age with severely calcified, stenotic de novo&#xD;
      coronary artery lesions presenting with stable, unstable, or silent ischemia that are&#xD;
      suitable for percutaneous coronary intervention (PCI) and with clinical characteristics&#xD;
      similar to the Disrupt CAD III IDE study. Approximately 1000 patients in the CathPCI&#xD;
      Registry® (including a minimum of 30 patients with permanent pacemakers [PPM] or implantable&#xD;
      cardioverter defibrillators [ICDs]) will be enrolled. Subjects will be followed through&#xD;
      discharge. A minimum of 150 patients will be followed 30 days post-procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>All-cause death</measure>
    <time_frame>Up to hospital discharge, approximately 24-48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedure-related adverse events</measure>
    <time_frame>Up to hospital discharge, approximately 24-48 hours</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Disrupt CAD III PAS Cohort</arm_group_label>
    <description>Patients in the CathPCI Registry who undergo a PCI procedure using a Shockwave C2 Coronary IVL catheter and meeting the eligibility criteria will be included in the PAS cohort. A minimum of 150 patients with 30-day follow-up will be included in the PAS cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shockwave C2 Coronary IVL</intervention_name>
    <description>PCI procedure using a Shockwave C2 coronary IVL catheter</description>
    <arm_group_label>Disrupt CAD III PAS Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severely calcified, stenotic de novo coronary artery lesions presenting with&#xD;
        stable, unstable, or silent ischemia that are suitable for percutaneous coronary&#xD;
        intervention (PCI) and with clinical characteristics similar to the Disrupt CAD III IDE&#xD;
        study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is ≥18 years of age&#xD;
&#xD;
          2. Subjects with native coronary artery disease (including stable or unstable angina and&#xD;
             silent ischemia) suitable for PCI&#xD;
&#xD;
          3. Left ventricular ejection fraction &gt;25% within 6 months&#xD;
&#xD;
          4. The target lesion must be a de novo coronary lesion that has not been previously&#xD;
             treated with any interventional procedure&#xD;
&#xD;
          5. LAD, RCA or LCX (or of their branches) with:&#xD;
&#xD;
               -  Stenosis of ≥70% and &lt;100% or&#xD;
&#xD;
               -  Stenosis ≥50% and &lt;99% (visually assessed) with evidence of ischemia via positive&#xD;
                  stress test, or fractional flow reserve (FFR) value ≤0.80, or iFR &lt;0.90 or IVUS&#xD;
                  or OCT minimum lumen area ≤4.0 mm²&#xD;
&#xD;
          6. The lesion length must not exceed 40 mm&#xD;
&#xD;
          7. The target vessel must have TIMI flow 3 at baseline (visually assessed; may be&#xD;
             assessed after pre-dilatation)&#xD;
&#xD;
          8. Evidence of calcification at the lesion site by angiography, with fluoroscopic&#xD;
             radio-opacities noted without cardiac motion prior to contrast injection involving&#xD;
             both sides of the arterial wall in at least one location&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject experienced an acute MI (STEMI or non-STEMI) within 30 days prior to index&#xD;
             procedure&#xD;
&#xD;
          2. New York Heart Association (NYHA) class III or IV heart failure&#xD;
&#xD;
          3. Renal failure with serum creatinine &gt;2.5 mg/dL or chronic dialysis&#xD;
&#xD;
          4. Subjects in cardiogenic shock or with clinical evidence of acute heart failure&#xD;
&#xD;
          5. Target lesion is located in a native vessel that can only be reached by going through&#xD;
             a saphenous vein or arterial bypass graft&#xD;
&#xD;
          6. Previous stent within target lesion (in-stent restenosis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Randee Randoll</last_name>
    <phone>408-577-7856</phone>
    <email>rrandoll@shockwavemedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>American College of Cardiology/National Cardiovascular Data Registry (NCDR)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NCDR Product Support</last_name>
      <phone>800-257-4737</phone>
      <email>ncdr@acc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intravascular Lithotripsy</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

